Welcome to our dedicated page for China Pharma news (Ticker: CPHI), a resource for investors and traders seeking the latest updates and insights on China Pharma stock.
China Pharma Holdings, Inc. reports developments tied to its specialty pharmaceutical business in China, where it develops, manufactures, and markets products for cardiovascular, central nervous system, infectious, and digestive diseases. News commonly centers on its wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., product portfolio updates, NMPA-related approvals, and dosage forms that include tablets, capsules, injectables, oral solutions, and other pharmaceutical products.
Company updates also cover the dry eye disease therapeutic device, completed generic-drug consistency evaluation for candesartan tablets, financing arrangements, convertible-note redemptions, and common-stock reverse splits. These announcements connect operating product activity with capital-structure actions for CPHI's NYSE American-listed common stock.
China Pharma Holdings (NYSE American: CPHI) closed its previously announced registered direct offering of 2,500,000 common shares at $2.00 per share, raising gross proceeds of $5.0 million before fees and expenses on July 23, 2026. According to the company, net proceeds will be used for working capital and general corporate purposes. FT Global Capital acted as exclusive placement agent, and the offering was conducted under an effective Form S-3 shelf registration.
China Pharma (NYSE American: CPHI) priced a registered direct offering of 2.5 million common shares at $2.00 per share, targeting gross proceeds of $5 million before fees and expenses. The company plans to use net proceeds for working capital and general corporate purposes.
The offering is expected to close on or about July 23, 2026, with FT Global Capital acting as exclusive placement agent. The transaction is being conducted under an effective Form F-3 shelf registration, with a prospectus supplement to be filed with the SEC.
China Pharma Holdings (NYSE American: CPHI) reported that the NYSE American contacted the company on July 21, 2026 regarding unusual trading activity in its common stock. The company stated it is not aware of any material corporate developments explaining this volatility and urged investors to rely on its SEC filings and official press releases.
China Pharma Holdings (NYSE American: CPHI) reported that NYSE American contacted the company following unusual trading activity in its common stock on July 10, 13, and 15, 2026. China Pharma stated it is not aware of any material nonpublic information or undisclosed business developments that would explain the recent market activity.
China Pharma (NYSE American: CPHI) reported that NYSE American contacted the company after unusual trading in its common stock on May 12–13, 2026. China Pharma stated it is not aware of any material nonpublic information or undisclosed business developments that would explain the recent market activity.
China Pharma Holdings (NYSE American: CPHI) has announced a 1-for-10 reverse stock split effective April 15, 2025. The company's Board of Directors authorized a reverse split ratio between 1:10 and 1:20 on October 22, 2024, which was approved by stockholders on December 22, 2024. The Board ultimately fixed the ratio at 1:10 on March 26, 2025.
Under this arrangement, every 10 shares of CPHI's issued and outstanding common stock will be automatically converted into one share. The stock will continue trading on NYSE American under the symbol 'CPHI' with a new CUSIP number: 16941T 401. Any fractional shares resulting from the split will be rounded up to the next whole number, ensuring that stockholders' percentage interests remain unchanged except for minor adjustments due to fractional share treatment.
China Pharma Holdings (NYSE American: CPHI) has announced the successful completion of all redemptions under its Convertible Promissory Note agreement with Streeterville Capital, as of December 11, 2024. The note, originally issued on November 17, 2021, had a principal amount of $5,250,000 and was later amended to extend its maturity date to August 19, 2025.
CEO and Chairwoman Zhilin Li emphasized that this milestone strengthens the company's financial foundation. The completion of these redemptions positions the company to pursue its growth objectives and continue developing innovative pharmaceutical solutions for the Chinese healthcare market.
China Pharma Holdings (NYSE American: CPHI) has announced an at-the-market equity offering through a Securities Purchase Agreement dated December 12, 2024. The company may sell up to $600,000 worth of common stock through December 31, 2024. The pricing will be determined by the lower of the previous day's closing price or the 5-day average closing price, with a minimum price of $0.15 per share.
The offering is made under a shelf registration statement that became effective on February 6, 2024. The timing and number of shares sold will depend on various factors determined by the investor, with no guarantee that the company will be able to sell any shares.
China Pharma Holdings, Inc. (NYSE American: CPHI) has announced plans to launch its Dry Eye Disease Therapeutic Device in China by Q1 2025. The device, developed by its subsidiary Hainan Helpson Medical and Biotechnology Co., , is a patented medical treatment for dry eye disease. With 400 million dry eye disease patients in China, the market is projected to reach $579.51 million by 2030, growing at a CAGR of 6.04% from 2023-2030.
The device uses ophthalmic oxygen-enriched atomization technology to spray tiny oxygen-rich droplets into the eyes, improving moisture, oxygen supply, and tear fluid quality. This physical therapy approach aims to avoid drug-related side effects while providing more direct and comfortable treatment.
Summary not available.